Search

Displaying results 4361 - 4370 of 10000 in total
  1. Drug

    GLB-004

    go.drugbank.com/drugs/DB32796
    Experimental

    GLB-004 is a molecular glue degrader targeting ARNT(HIF-1β).[L56125, L56126]

  2. Drug

    GLB-005

    go.drugbank.com/drugs/DB32797
    Experimental

    GLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]

  3. Drug

    GLB-007

    go.drugbank.com/drugs/DB32798
    Experimental

    GLB-007 is a molecular glue degrader targeting WIZ and ZBTB7A.[L56125, L56126, L56128]

  4. Drug

    GLB-006

    go.drugbank.com/drugs/DB32799
    Experimental

    GLB-006 is a molecular glue degrader targeting NEK7.[L56125, L56126]

  5. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  6. Drug

    APT20TTMG

    go.drugbank.com/drugs/DB32869
    Experimental

    APT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.

  7. Drug

    RS5441

    go.drugbank.com/drugs/DB33178
    Experimental

    RS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]

  8. Drug

    Enlimomab

    go.drugbank.com/drugs/DB33731
    Experimental

    Categories: Intercellular Adhesion Molecule-1
  9. Drug

    MOPEVAC-Las

    go.drugbank.com/drugs/DB33987
    Experimental

    MOPEVAC-Las is a biologic drug. … MOPEVAC-Las is under investigation in clinical trial NCT07833436 (A Randomized, Placebo-controlled Trial, to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against

  10. Drug

    VV-14300

    go.drugbank.com/drugs/DB33996
    Experimental

    VV-14300 is a biologic drug. VV-14300 is under investigation in clinical trial NCT07829302 (VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes).